A Phase 3 interventional study of Denosumab and Placebo in Hormone Refractory Prostate Cancer, sponsored by Amgen. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Amgen · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing denosumab in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Denosumab · Prostatic Neoplasms.
Among the 10 studies testing denosumab in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2006, is one of 8 in phase 3, and was the 2nd registered.
7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 10 studies testing denosumab in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,435 is above the median of 60 across 5,354 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 324 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
23 studies in Prostatic Neoplasms by Amgen: 4 open now, 7 under way, 2 of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2006, is one of 9 in phase 3, and was the 4th registered.
Amgen’s Prostatic Neoplasms studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing denosumab in Prostatic Neoplasms, from their registry updates:
Among Amgen’s 23 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the treatment effect of denosumab with placebo on prolonging bone metastasis-free survival in men with hormone refractory (androgen independent) prostate cancer who have no bone metastasis at baseline.
Participants were randomized to receive denosumab 120 mg or placebo every 4 weeks (Q4W) until approximately 660 participants developed bone metastasis or died and the primary efficacy and safety analyses were completed.
All participants undergoing scheduled assessments were offered open-label denosumab 120 mg subcutaneous (SC) until they either developed a bone metastasis, obtained access to commercially available product in this setting, or for up to 3 years, whichever came first. For participants who ended participation before the open-label extension (OLE) phase or withdrew from investigational product during the OLE phase, their survival data was to be collected every 6 months for up to 3 years after their last dose of investigational product.
Participants in the Czech Republic and United Kingdom were enrolled under a separate protocol for the OLE phase per Health Authority request, and are reported separately (Study 20080585; NCT01824342).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injections every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
Biological: Placebo
Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
Biological: Denosumab
Administered by subcutaneous injection
Also known as: XGEVA®
Same volume subcutaneous injection
Bone Metastasis-free Survival
The time to the first occurrence of bone metastasis (either symptomatic or asymptomatic) or death from any cause. Participants who did not experience bone metastasis or on-study death were censored at the last on-study contact date or the primary analysis data cutoff date, whichever came first. Median bone metastasis-free survival time was estimated using the Kaplan-Meier method.
Time frame: From the first dose of investigational product to the primary data cutoff date of 30 July 2010; median time on study was approximately 20 months.
Time to First Bone Metastasis
Time from randomization to the date of first occurrence of bone metastasis (either symptomatic or asymptomatic), excluding death. Participants who did not develop bone metastasis were censored at their last on-study bone assessment date or the primary analysis data cut-off date, whichever was first. Median time to first bone metastasis was estimated using the Kaplan-Meier method.
Time frame: From the first dose of investigational product to the primary data cutoff date of 30 July 2010; median time on study was approximately 20 months.
Overall Survival
Time from randomization to the date of death. Participants who were still alive or lost to follow-up by the primary analysis data cut-off date were censored at their last contact date (on-study or during survival follow-up) or the primary analysis data cut-off date, whichever was first.
Time frame: From the first dose of investigational product to the primary data cutoff date of 30 July 2010; median time on study was approximately 20 months.
Eligible subjects were men ≥ 18 years old with histologically-confirmed, castrate-resistant prostate cancer who were chemically or surgically castrated. The first patient was enrolled into the study on 03 February 2006 and the last patient was enrolled on 23 July 2008.
| Milestone | Placebo | Denosumab |
|---|---|---|
| Started | 716 | 716 |
| Received treatment | 709 | 716 |
| On study at primary data analysis cutoff | 164 | 174 |
| Completed | 132 | 123 |
| Not completed | 584 | 593 |
| Withdrew: Withdrawal by subject | 103 | 113 |
| Withdrew: Protocol-specified criteria | 307 | 269 |
| Withdrew: Death | 58 | 65 |
| Withdrew: Adverse event | 28 | 40 |
| Withdrew: Disease progression | 22 | 35 |
| Withdrew: Other | 25 | 33 |
| Withdrew: Administrative decision | 20 | 21 |
| Withdrew: Noncompliance | 8 | 8 |
| Withdrew: Lost to follow-up | 11 | 4 |
| Withdrew: Protocol deviation | 1 | 3 |
| Withdrew: Ineligibility determined | 1 | 2 |
| Milestone | Placebo | Denosumab |
|---|---|---|
| Started | 110 | 104 |
| Received treatment | 109 | 101 |
| Completed | 33 | 33 |
| Not completed | 77 | 71 |
| Withdrew: Physician decision | 24 | 21 |
| Withdrew: Adverse event | 5 | 16 |
| Withdrew: Other | 11 | 11 |
| Withdrew: Withdrawal by subject | 14 | 10 |
| Withdrew: Death | 10 | 7 |
| Withdrew: Disease progression | 9 | 3 |
| Withdrew: Noncompliance | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol-specified criteria | 1 | 0 |
| Withdrew: Missing end of study information | 0 | 1 |
The time to the first occurrence of bone metastasis (either symptomatic or asymptomatic) or death from any cause. Participants who did not experience bone metastasis or on-study death were censored at the last on-study contact date or the primary analysis data cutoff date, whichever came first. Median bone metastasis-free survival time was estimated using the Kaplan-Meier method.
| days | Placebo | Denosumab |
|---|---|---|
| Bone Metastasis-free Survival | 768.0 (675.00 to 897.00) | 897.00 (773.00 to 1014.00) |
Time from randomization to the date of first occurrence of bone metastasis (either symptomatic or asymptomatic), excluding death. Participants who did not develop bone metastasis were censored at their last on-study bone assessment date or the primary analysis data cut-off date, whichever was first. Median time to first bone metastasis was estimated using the Kaplan-Meier method.
| days | Placebo | Denosumab |
|---|---|---|
| Time to First Bone Metastasis | 897.0 (683.00 to 1009.00) | 1010.0 (897.00 to 1156.00) |
Time from randomization to the date of death. Participants who were still alive or lost to follow-up by the primary analysis data cut-off date were censored at their last contact date (on-study or during survival follow-up) or the primary analysis data cut-off date, whichever was first.
| days | Placebo | Denosumab |
|---|---|---|
| Overall Survival | 1365.0 (1220.00 to NA) | 1335.0 (1221.00 to NA) |
Collected over Median investigational product exposure was 18.4 and 19.3 months in the placebo and denosumab groups respectively during the double blind phase and 23.7 and 24.9 months during the open-label treatment phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB: Placebo | — | 332/705 (47.1%) | 585/705 (83%) |
| DB: Denosumab 120 mg Q4W | — | 341/720 (47.4%) | 599/720 (83.2%) |
| OLE: Placebo/ Denosumab 120 mg Q4W | — | 39/109 (35.8%) | 80/109 (73.4%) |
| OLE: Denosumab/ Denosumab 120 mg Q4W | — | 36/101 (35.6%) | 74/101 (73.3%) |
| Event | DB: Placebo | DB: Denosumab 120 mg Q4W | OLE: Placebo/ Denosumab 120 mg Q4W | OLE: Denosumab/ Denosumab 120 mg Q4W |
|---|---|---|---|---|
| Urinary retentionRenal and urinary disorders | 33/705 | 56/720 | 6/109 | 5/101 |
| HaematuriaRenal and urinary disorders | 25/705 | 37/720 | 2/109 | 5/101 |
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 0/705 | 12/720 | 1/109 | 5/101 |
| Myocardial infarctionCardiac disorders | 10/705 | 12/720 | 4/109 | 1/101 |
| Renal failure acuteRenal and urinary disorders | 16/705 | 12/720 | 4/109 | 2/101 |
| Prostatic obstructionReproductive system and breast disorders | 2/705 | 0/720 | 4/109 | 0/101 |
| AnaemiaBlood and lymphatic system disorders | 12/705 | 25/720 | 2/109 | 3/101 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 21/705 | 15/720 | 1/109 | 1/101 |
| Urinary tract infectionInfections and infestations | 15/705 | 15/720 | 2/109 | 3/101 |
| DehydrationMetabolism and nutrition disorders | 9/705 | 7/720 | 0/109 | 3/101 |
| Event | DB: Placebo | DB: Denosumab 120 mg Q4W | OLE: Placebo/ Denosumab 120 mg Q4W | OLE: Denosumab/ Denosumab 120 mg Q4W |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 159/705 | 166/720 | 24/109 | 8/101 |
| ConstipationGastrointestinal disorders | 124/705 | 128/720 | 13/109 | 15/101 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 116/705 | 123/720 | 11/109 | 9/101 |
| HaematuriaRenal and urinary disorders | 90/705 | 87/720 | 17/109 | 11/101 |
| DiarrhoeaGastrointestinal disorders | 102/705 | 110/720 | 8/109 | 10/101 |
| Urinary tract infectionInfections and infestations | 96/705 | 108/720 | 15/109 | 14/101 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 88/705 | 101/720 | 12/109 | 10/101 |
| NauseaGastrointestinal disorders | 95/705 | 98/720 | 4/109 | 14/101 |
| FatigueGeneral disorders | 82/705 | 98/720 | 5/109 | 8/101 |
| Oedema peripheralGeneral disorders | 88/705 | 94/720 | 5/109 | 11/101 |
| Age, Continuous(years) | Placebo | Denosumab | Total |
|---|---|---|---|
| Mean | 73.2 ± 8.3 | 73.2 ± 8.8 | 73.2 ± 8.6 |
| Sex: Female, Male(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 716 | 716 | 1432 |
| Race/Ethnicity, Customized(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| White or Caucasian | 604 | 606 | 1210 |
| Black or African American | 35 | 41 | 76 |
| Hispanic or Latino | 37 | 32 | 69 |
| Asian | 18 | 17 | 35 |
| Japanese | 2 | 0 | 2 |
| American Indian or Alaska Native | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Other | 17 | 18 | 35 |
| Unknown | 0 | 2 | 2 |
| Eastern Cooperative Oncology Group (ECOG)Pperformance Status(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Grade 0 | 514 | 505 | 1019 |
| Grade 1 | 199 | 210 | 409 |
| Grade 2 | 3 | 1 | 4 |
| Grade 3 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 |
| Prostate-Specific Antigen (PSA) Doubling Time(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| ≤ 10 months | 580 | 574 | 1154 |
| > 10 months | 136 | 142 | 278 |
| Prostate-Specific Antigen (PSA) ≥ 8.0 ng/mL(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Yes | 471 | 473 | 944 |
| No | 245 | 243 | 488 |
| Prior Chemotherapy Regimens(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Yes | 54 | 63 | 117 |
| No | 662 | 653 | 1315 |
No study locations are listed for this record.
Ran from Jan 2006 to primary completion in Jul 2010, 54 months.
Results were first posted in Apr 2015, 4 years 8 months after primary completion. A results delay was requested in May 2011.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 54 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab